Ilmarinen Mutual Pension Insurance Co Raises Stock Position in Pfizer Inc. $PFE

Key Points

• Ilmarinen Mutual Pension Insurance Co boosted its Pfizer stake by 4.5% in the fourth quarter, buying 40,000 additional shares and bringing its total holdings to 927,000 shares worth about $23.1 million.
• Pfizer’s stock has drawn mixed analyst views, with a consensus rating of Hold and an average price target of $28.82; some firms recently raised targets or upgraded the stock while others remain cautious.
• The company beat quarterly earnings and revenue estimates, reported $0.75 EPS on $14.45 billion in revenue, and also announced a quarterly dividend of $0.43 per share, implying a 6.6% annual yield.

Ilmarinen Mutual Pension Insurance Co increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 4.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 927,000 shares of the biopharmaceutical company's stock after acquiring an additional 40,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Pfizer were worth $23,082,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after buying an additional 7,031,162 shares in the last quarter. State Street Corp grew its holdings in shares of Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock worth $7,620,747,000 after buying an additional 2,786,098 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock worth $3,235,642,000 after buying an additional 1,184,728 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock worth $1,631,225,000 after buying an additional 869,175 shares in the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Pfizer by 5.4% during the fourth quarter. Fisher Asset Management LLC now owns 51,952,106 shares of the biopharmaceutical company's stock worth $1,293,607,000 after buying an additional 2,664,052 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PFE. Argus raised shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price for the company in a report on Monday, March 2nd. UBS Group reaffirmed a "neutral" rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday. Guggenheim upped their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and set a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $28.82.

Pfizer Trading Down 0.2%

Shares of PFE stock opened at $26.16 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market cap of $149.07 billion, a PE ratio of 19.97 and a beta of 0.35. The company has a 50-day moving average of $26.79 and a two-hundred day moving average of $26.28. Pfizer Inc. has a 1-year low of $23.06 and a 1-year high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer's revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer and Innovent Biologics announced a global licensing and collaboration deal to research and develop 12 early-stage cancer medicines, with potential value of up to $10.5 billion. The agreement expands Pfizer’s oncology pipeline and could create long-term revenue opportunities. Reuters article
• Positive Sentiment: The companies also described the partnership as a strategic global collaboration covering ADCs and multi-specific antibodies, which suggests Pfizer is strengthening its next-generation cancer portfolio. PR Newswire article
• Positive Sentiment: Recent coverage also highlighted steady early-stage pipeline progress, including a new Phase 1 trial update, reinforcing the view that Pfizer has several development programs moving forward. TipRanks article
• Neutral Sentiment: Bank of America recently lifted its price target on Pfizer to $27 from $26 after stronger quarterly results, indicating slightly improved sentiment but still a cautious overall stance. Yahoo Finance article

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.